Objective: To identify the stage of Hepatocellular Carcinoma (HCC) at the time of presentation. Methods: This cross sectional observational prospective study was carried out at Gastro Department of Combined Military Hospital (CMH) Multan from August 2017 to December 2018. Patients were diagnosed on the basis of alpha fetoprotein, abdominal ultrasound, triphasic contrast enhanced computerized tomography (CECT). They were evaluated for etiology including Hepatitis B, C and non B & C. The patients were inquired about the previous treatment and when they came to know about the HCC. Staging of the tumor was done on the basis BCLC (Barcelona cancer liver clinic) and Melan’s criteria. Performance status (PS) of the patient was checked by Eastern Cooperative Oncology Group (ECOG) criteria. Severity of cirrhosis was assessed by CTP (Child Turcotte Pugh) and Model for end stage liver disease (MELD) score. The data was analyzed in IBM SPSS version 22. Results: Out of 135 patients 78% were males and 22% females. Age Mean SD was 58.81± 9.366. Frequency of hepatitis C, B, combined B, C and non-B non-C was 80%, 11%, 2.8% and 6.2% respectively. 96(73.8%) never got the treatment before for Hepatitis. 81(62.3%) came to know first time on this index admission. Maximum numbers of patients were in BCLC stage B i.e. 82(55.2%) with ECOG grade of one i.e.57 (39.3%), at the time of presentation. Mean MELD and CTP score were 12.24, 7.34 (class B) respectively. Conclusion: HCV was the most common in HCC, never treated before, presented for the first time in advance stage of the disease where very limited treatment options left behind. doi: https://doi.org/10.12669/pjms.36.3.1594 How to cite this:Hafeez M, Nadeem M, Ahmed M, Faheem-ur-Rehman. Hepatocellular Carcinoma (HCC), Where do we stand? Current situation. Pak J Med Sci. 2020;36(3):---------. doi: https://doi.org/10.12669/pjms.36.3.1594 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
展开▼
机译：目的：鉴定介绍时肝细胞癌（HCC）的阶段。方法：这项横断面观测前瞻性研究于2017年8月至2018年8月，在胃肠部（CMH）Multan组合的Multan中进行了诊断患者。患者是在α胎儿蛋白，腹部超声，三足球对比增强的计算机断层扫描（CECT）的基础上进行诊断出来。他们被评估为病因，包括乙型肝炎，C和非B＆C.患者询问了先前的治疗，当他们对HCC了解时。肿瘤的分期在BCLC（巴塞罗那癌症肝诊所）和Melan标准的基础上进行。东方合作肿瘤组（ECOG）标准检查患者的性能状态（PS）。 CTP（儿童Turcotte Pugh）和末期肝病（MELD）评分的模型评估了肝硬化的严重程度。在IBM SPSS版本22中分析了数据。结果：135名患者中的78％是男性和22％的女性。年龄平均SD为58.81±9.366。丙型肝炎，B，B组，C和非B非C的频率分别为80％，11％，2.8％和6.2％。 96（73.8％）从未在肝炎之前进行治疗。 81（62.3％）在本指数中首次了解。最大数量的患者在BCLC阶段B中，E.57（55.2％）在介绍时，ECOG等级（39.3％）。平均融合和CTP评分分别为12.24,7.34（b级）。结论：HCV在HCC中最常见，以前从未治疗过，在疾病的第一次提前呈现，留下了非常有限的治疗方案。 Doi：https://doi.org/10.12669/pjms.36.3.1594如何引用这个：Hafeez M，Nadeem M，Ahmed M，Faheem-Ur-Rehman。肝细胞癌（HCC），我们站在哪里？现在的情况。 Pak J Med Sci。 2020; 36（3）：---------。 DOI：https://doi.org/10.12669/pjms.36.3.1594这是一个在Creative Commons归因许可（http://creativecommons.org/licenses/3.0）的条款下分发的开放式访问文章，哪些只要正确引用原始工作，允许在任何媒体中不受限制使用，分发和再现。
展开▼
